NCT05376683

AI for Anti-hypertensive Medication Titration

Status unknown NA Last updated 6 May 2023

What this trial tests

NA trial testing Curate.AI in Hypertension in 45 participants. Status unknown.

Timeline

1 April 2023

Primary endpoint
20 February 2024

20 April 2024

Quick facts

Lead sponsor	Alexandra Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	other
Enrollment	45
Start date	1 April 2023
Primary completion	20 February 2024
Estimated completion	20 April 2024
Sites	1 location across Singapore

Drugs / interventions tested

• Curate.AI
• Telemonitoring

Conditions studied

• Hypertension — all drugs for Hypertension →
• Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Alexandra Hospital

Who can join

Adults 30 to 80, any sex, with Hypertension or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypertension - a chronic condition of elevated blood pressure (BP) - is a highly prevalent condition. However, effective prevention and management of hypertension remain challenging under the current standard of care (SOC). There has been a growing recognition that one-off, irregular office BP measurements are not sufficient and that regular home BP monitoring will likely be an adjunct to conventional office BP measurements. By using artificial intelligence (AI), via the CURATE.AI platform, the goal is to use patients' BP data to rapidly generate personalized anti-hypertensive dose titrations. The main aim of this study is to assess the feasibility of CURATE.AI-assisted dose titration.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial.
   Blasiak A, Tan LWJ, Chong LM, Tadeo X, et al · · 2024 · cited 8× · PMID 39191913 · DOI 10.1038/s41746-024-01195-5
2. CURATE.AI-assisted dose titration for anti-hypertensive personalized therapy: study protocol for a multi-arm, randomized, pilot feasibility trial using CURATE.AI (CURATE.AI ADAPT trial).
   Truong ATL, Tan SB, Wang GZ, Yip AWJ, et al · · 2024 · cited 7× · PMID 38264697 · DOI 10.1093/ehjdh/ztad063
3. Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial.
   Blasiak A, Truong ATL, Foo N, Tan LWJ, et al · · 2025 · cited 6× · PMID 39984618 · DOI 10.1038/s41698-025-00835-7
4. N-of-1 medicine.
   Wang P, Leong QY, Lau NY, Ng WY, et al · · 2024 · cited 5× · PMID 38527301 · DOI 10.4103/singaporemedj.smj-2023-243